🔗 Share this article

While the US undertakes historic changes to its immunization schedules, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American sports physician and epidemiologist who initially gained attention by questioning Covid vaccinations during the global health crisis and has concentrated on possible fatalities following Covid immunization in her recent tenure at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Program

Agency leaders planned to reveal major changes to the childhood immunization program earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US out of step with many the world with no evidence for benefit. This reveal has been delayed until the next year.

Rather than the director of the vaccine center, Høeg is listed to speak at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to run the center this year.

A New Direction at the Agency

The acting appointment may indicate a tighter collaboration between the pharmaceutical and biologics branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for discontinuing some pediatric vaccine recommendations in the US in order to be more similar to Denmark, a society with nationalized medicine and a citizenry about the size of Wisconsin’s.

To date comments, she has persisted in emphasizing on vaccines – typically the purview of Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has no apparent background in pharmaceutical research, oversight or management, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in leading a major agency. She has no expertise in pharmaceutical oversight.”

Previous directors of the center would “be deeply familiar with laws and regulations and the science of medication creation”, noted Janet Woodcock. “Frankly, she has not acquired the sort of resume that previous people who headed the center have had.”

This division has an enormous range of responsibilities at the agency, she stated.

“Many people just zeroes in on the innovative therapies, but the generic drug division clears numerous generic drugs. There’s a biosimilars division, over-the-counter program and so forth, and each of these have to be looked after,” Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a major management component to the role, which supervises over 5,000 staff members. “It’s a massive leadership role, if you perform it correctly,” the former official concluded.

Official Statement and Contentious Initiatives

When asked about concerns about Høeg’s qualifications and whether this assignment indicates increased cooperation among FDA leaders on vaccines, a representative said that the “questions rely on inaccurate premises”.

“Her resume is consistent with the duties of her role,” the representative explained, citing the time Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the commissioner’s controversial expedited review system, a disputed one-day drug-approval program that apparently troubled her preceding directors. “How are these therapies being chosen for this voucher program? Who takes the calls?” Dr. Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

In general, he remarked, “the FDA appears to be shifting towards laxer regulations of pharmaceuticals, except for shots.”

Established Past Work on Immunizations

Regarding immunizations, Høeg has a more documented, if problematic, history, critics have noted. She published a research paper using unverified crowd-sourced reports to determine the incidence of myocarditis after COVID-19 immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the incoming government encompassed revising regulations for novel immunizations and halting “optional” vaccines, she stated after the election on a audio program. At the FDA, Høeg has reportedly proposed preventing young men from getting Covid vaccines.

“She’s an complete dogmatist who commences with her preconceived notions and tailors the evidence to accommodate the data in a extremely misleading, dishonest manner,” Howard argued.

Taking Control and a “Push for Payback”

Høeg became part of other dissenters, {like|